7 news items
On May 14, 2024, Paragon Therapeutics Announced A License Agreement Granting Spyre Therapeutics An Exclusive License To Certain Antibodies And Products Targeting α4SS7 Integrin And Tl1A, Paragon Will Up To $22M In Milestone Payments-8K
SYRE
15 May 24
by the Company; on material breach without cure; and to the extent permitted by law, on a party’s insolvency or bankruptcy
Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors
SYRE
15 May 24
assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements
Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
SYRE
9 May 24
the impact of all factors on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially
Spyre Therapeutics Announces Grants of Inducement Awards
SYRE
3 May 24
on May 1, 2024 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4
Spyre Therapeutics Announces Grants of Inducement Awards
SYRE
1 Apr 24
on April 1, 2024 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4
ctt3b8infjr2t270vupahf
APGE
AVAV
CEG
5 Mar 24
York Community Bancorp last week announced that it identified material weaknesses in its internal controls and replaced its CEO.
Spyre
1ze3mu20znag z44x77l2ekrbi9atblk6p03q
SYRE
1 Mar 24
on March 1, 2024 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c
- Prev
- 1
- Next